Pembrolizumab biosimilar(R-Pharm)

帕博利珠单抗生物类似药（R-Pharm）

Report date: 2024/03/21 20:00:29

Base Information

Drug NamePembrolizumab biosimilar(R-Pharm)

Drug Alias NameRPH-075

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesR-Pharm Jsc

China Registration ClassN/A

Active CompaniesR-Pharm Jsc

Inactive CompaniesN/A

Active IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck

Inactive IndicationsN/A

ATC CodeL01FF02L01XC18